Cannabidiol: State of the art and new challenges for therapeutic applications

Pisanti, Simona; Malfitano, Anna Maria; Ciaglia, Elena; Lamberti, Anna; Ranieri, Roberta; Cuomo, Gaia; Abate, Mario; Faggiana, Giorgio; Proto, Maria; Fiore, Donatella; Laezza, Chiara; Bifulco, Maurizio

doi:10.1016/j.pharmthera.2017.02.041

Cited by 483 publications

(424 citation statements)

References 239 publications

Supporting

Mentioning

368

Contrasting

Unclassified

Order By: Relevance

“…On CB2 receptors, CBD can act as receptor-inverse agonist. This may explain, at least in part, its anti-inflammatory effects and its inhibition of the migration of macrophages, microglial cells and neutrophils [18]. CBD shares with Riluzole effects on ion channels that are responsible for repetitive firing and transmitter release [19].…”

Section: Discussionmentioning

confidence: 99%

Co-medication with Cannabidiol May Slow Down the Progression of Motor Neuron Disease: A Case Report

Nahler¹

2017

J Gen Pract

View full text Add to dashboard Cite

Amyotrophic lateral sclerosis (ALS, also called Charcot disease, Lou Gehrig disease), is a progressive, neurodegenerative disease caused by the degeneration of motor neurons in the brain and spinal cord. There is no cure. This report describes a case of motor neuron disease with typical weakness in one leg, one hand and the tongue. Despite of treatment with riluzole, symptoms progressed relatively fast. Therefore, the patient decided to take cannabidiol (CBD, 2 × 200 mg/day) as co-medication, which was started 8 weeks after riluzole, and increased to a daily dose of 2 × 300 mg. Within 6 weeks, the impaired function of the right hand and foot reversed almost completely and dysphagia partially. Improvement was maintained for about 10 weeks, when again a slow progression of dysarthria and dysphagia was observed. Eighteen months after onset, speech is almost completely lost, and dysphagia also progressed. However, symptoms of the limbs (weakness, fasciculation, atrophy) worsened much less. It is concluded, that Co-medication with CBD may be able to slow down the progression of some but not all symptoms of motor neuron disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Co-medication with Cannabidiol May Slow Down the Progression of Motor Neuron Disease: A Case Report

Nahler¹

2017

J Gen Pract

View full text Add to dashboard Cite

show abstract

“…The majority of studies attributed the potential antipsychotic properties of CBD to its ability to directly inhibit the reuptake of anandamide, an endocannabinoid that exhibits neurogenic and anti-inflammatory activity (Pisanti et al 2017) and plays a major role in mood regulation, cognition and behaviour (Di Marzo & Petrosino, 2007). Moreover, CBD can also reduce endocannabinoids degradation by blocking fatty acid amide hydrolase function (Pisanti et al 2017).…”

Section: Cbd and Psychosismentioning

confidence: 99%

“…Moreover, CBD can also reduce endocannabinoids degradation by blocking fatty acid amide hydrolase function (Pisanti et al 2017). Consequently, the increase of endocannabinoids, such as anandamide, in postsynaptic neurons may regulate presynaptic release of γ-aminobutyric acid and glutamate as well as stabilise dopamine neurotransmission (Gururajan & Malone, 2016).…”

Section: Cbd and Psychosismentioning

confidence: 99%

Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview

Mandolini

Lazzaretti

Pigoni

et al. 2018

Epidemiol Psychiatr Sci

View full text Add to dashboard Cite

This Section of Epidemiology and Psychiatric Sciences appears in each issue of the Journal to stress the relevance of epidemiology for behavioral neurosciences, reporting the results of studies that explore the use of an epidemiological approach to provide a better understanding of the neural basis of major psychiatric disorders and, in turn, the utilisation of the behavioural neurosciences for promoting innovative epidemiological research.The ultimate aim is to help the translation of most relevant research findings into every-day clinical practice. These contributions are written in house by the journal's editorial team or commissioned by the Section Editor (no more than 1000 words, short unstructured abstract, 4 key-words, one Cannabidiol (CBD) represents a new promising drug due to a wide spectrum of pharmacological actions. In order to relate CBD clinical efficacy to its pharmacological mechanisms of action, we performed a bibliographic search on PUBMED about all clinical studies investigating the use of CBD as a treatment of psychiatric symptoms. Findings to date suggest that (a) CBD may exert antipsychotic effects in schizophrenia mainly through facilitation of endocannabinoid signalling and cannabinoid receptor type 1 antagonism; (b) CBD administration may exhibit acute anxiolytic effects in patients with generalised social anxiety disorder through modification of cerebral blood flow in specific brain sites and serotonin 1A receptor agonism; (c) CBD may reduce withdrawal symptoms and cannabis/tobacco dependence through modulation of endocannabinoid, serotoninergic and glutamatergic systems; (d) the preclinical pro-cognitive effects of CBD still lack significant results in psychiatric disorders. In conclusion, current evidences suggest that CBD has the ability to reduce psychotic, anxiety and withdrawal symptoms by means of several hypothesised pharmacological properties. However, further studies should include larger randomised controlled samples and investigate the impact of CBD on biological measures in order to correlate CBD's clinical effects to potential modifications of neurotransmitters signalling and structural and functional cerebral changes.

show abstract

“…It has been shown to be anxiolytic, antidepressant, antipsychotic, anticonvulsant, anti-nausea, antioxidant, antiinflammatory, anti-arthritic, anti-neoplastic, and protective in animal models of epilepsy, anxiety, psychosis, and basal ganglia diseases (Ligresti, De Petrocellis, & Di Marzo, 2016). Anti-cancer effects have also been shown (Pisanti et al, 2017). Research involving CBD has burgeoned in recent years (Burstein, 2015;Zuardi, 2008).…”

Section: ____________________________________________________________mentioning

confidence: 99%

Synthetic cannabinoids severely elevate amino transferase levels. Natural cannabidiol does not.

Cushing¹,

Joseph²

2018

View full text Add to dashboard Cite

Abstract:Cannabidiol (CBD) is a promising and well-studied medicinal compound found in cannabis. While CBD has a favorable safety profile, the deleterious health effects of synthetic cannabinoids are well documented. The human body is not equipped with the tools needed to catabolize synthetic cannabinoids. Among the enzymes recruited to removing them from the body are Alanine Amino Transferase (ALT) and Aspartate Amino Transferase (AST). The present article is broken into one naturalistic medical observation, and two studies. Each of these is concerned with the ALT and AST levels of patients exposed to cannabinoids. The medical observation is of four patients who mistakenly consumed a dangerous synthetic cannabinoid, JWH-018. Their ALT and AST levels were recorded once. The first experimental study is of six patients that consumed a synthetic CBD derivative, H4-CBD. ALT and AST levels were recorded over 22 weeks. The second experimental study is of 184 patients that consumed natural CBD. ALT and AST levels were recorded over 6 months. Taken together, these studies demonstrate clear differences between consumption of natural CBD, and two synthetic derivatives on ALT and AST levels.

show abstract

Cannabidiol: State of the art and new challenges for therapeutic applications

Cited by 483 publications

References 239 publications

Co-medication with Cannabidiol May Slow Down the Progression of Motor Neuron Disease: A Case Report

Co-medication with Cannabidiol May Slow Down the Progression of Motor Neuron Disease: A Case Report

Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview

Synthetic cannabinoids severely elevate amino transferase levels. Natural cannabidiol does not.

Contact Info

Product

Resources

About